Antiplatelet Therapy for Old Inferior Wall Myocardial Infarction

Primary Recommendation

The American College of Cardiology/American Heart Association recommends aspirin 75-100 mg daily lifelong after the initial period of dual antiplatelet therapy in patients with prior myocardial infarction (Class I, Level A recommendation) 1
The American College of Cardiology/American Heart Association guidelines specify that aspirin should be started at 75-162 mg daily and continued indefinitely in all post-myocardial infarction patients unless contraindicated (Class I, Level A) 2
This recommendation applies regardless of the location of the infarction (inferior, anterior, or other territories) 2

The European Society of Cardiology recommends clopidogrel 75 mg daily as a safe and effective alternative to aspirin monotherapy in patients with prior myocardial infarction (Class I, Level A recommendation) 1

The European Heart Journal recommends using 75-100 mg daily for long-term maintenance of aspirin after any initial higher-dose period during the acute phase 1
The American College of Cardiology/American Heart Association recommends lower maintenance doses (81 mg) of aspirin over higher doses (325 mg) to minimize bleeding risk without compromising efficacy 2

The American College of Cardiology/American Heart Association and the European Heart Journal recommend that antiplatelet therapy should be continued indefinitely in all patients with prior myocardial infarction unless contraindications develop 2, 1
The European Heart Journal indicates that the term "old" myocardial infarction (remote from the acute event and beyond the initial dual antiplatelet therapy period) means the patient should be on single antiplatelet therapy, not dual therapy 1

The American College of Cardiology/American Heart Association recommends aspirin 75-100 mg daily as the first choice, which is the most widely studied, cost-effective, and guideline-recommended option 2, 1
The European Heart Journal recommends clopidogrel 75 mg daily as an equivalent alternative to aspirin monotherapy in patients with prior myocardial infarction 1

The European Heart Journal indicates that for an "old" inferior wall myocardial infarction (remote from the acute event), the patient should be beyond the initial dual antiplatelet therapy period 1
The European Heart Journal recommends that dual antiplatelet therapy is only indicated for up to 6 months post-percutaneous coronary intervention with stenting (or up to 12 months in selected high-risk cases), not for chronic long-term management 1

Both medications have similar safety profiles, with no significant difference in major extracranial bleeding (RR 0.88, 95% CI 0.7-1.12) 3

The European Society of Cardiology recommends clopidogrel 75 mg daily as a safe and effective alternative to aspirin monotherapy for patients with established cardiovascular disease (Class I, Level A recommendation) 4
For patients with chronic coronary syndrome and prior myocardial infarction or remote percutaneous coronary intervention, both aspirin 75-100 mg daily and clopidogrel 75 mg daily are recommended as effective long-term antiplatelet options 4
For patients with established coronary artery disease, including those after the first year post-acute coronary syndrome, long-term single antiplatelet therapy with either aspirin 75-100 mg daily or clopidogrel 75 mg daily is recommended over no antiplatelet therapy (Grade 1A) 3, 5

In patients with aspirin intolerance or allergy, clopidogrel is the preferred alternative 6
For patients with symptomatic or asymptomatic peripheral arterial disease or history of ischemic stroke/TIA, clopidogrel may offer greater benefit than aspirin 7
When dual antiplatelet therapy is required, the combination of aspirin 75-100 mg with clopidogrel 75 mg is recommended, with duration based on clinical context and stent type 5

For most patients with established cardiovascular disease, either aspirin 75-100 mg daily or clopidogrel 75 mg daily is appropriate 4, 3
Consider clopidogrel as the preferred option for patients with aspirin intolerance or allergy 6
Consider clopidogrel as the preferred option for patients with history of ischemic stroke/TIA 7

Do not use ibuprofen with aspirin as it blocks aspirin's antiplatelet effects 6
Clopidogrel requires hepatic conversion to its active metabolite, which may be affected by genetic polymorphisms or drug interactions 7
For patients requiring dual antiplatelet therapy, the duration should be limited to the recommended period to minimize bleeding risk 4, 5